Strengths and Characteristics
The ethical drug business is driven primarily by KYORIN Pharmaceutical, which uses its franchise customer strategy in focusing on respiratory medicine, otolaryngology, and urology. By concentrating resources on these key fields, and pursuing customer-centric, rather than product-centric sales activities, we seek to improve the accuracy of our customer targeting, consistently provide finely-tuned customer service, and strengthen the competitiveness of our domestic business base.
In research and development, we focus on developing new drugs, leveraging the highly creative drug discovery capabilities for which we have received global recognition.
Industry Trends
While the domestic pharmaceutical industry is seeing the establishment of a new policy regarding premiums for promoting new drug creation and the elimination of off-label drug use, which in real terms will help maintain new drug prices, additional reductions to the price of longstanding items on the NHI drug price list, and further measures to promote the use of generic drugs, represent major changes in the business environment.
KYORIN Pharmaceutical Co., Ltd.
KYORIN Pharmaceutical Co., Ltd.
KYORIN Pharmaceutical envisions itself as a drug manufacturer that is trusted by patients and medical professionals, and is recognized for its presence in society. To achieve that, we are working to enhance our presence in specific fields, including respiratory medicine, otolaryngology, and urology, while discovering new, original drugs on a global basis. In sales, we are deploying a franchise customer strategy, focusing again on the key areas of respiratory medicine, otolaryngology, and urology. By focusing resources in these key areas, we are working to strengthen the competitiveness of our domestic sales base, utilizing around 750 medical representatives to provide customer-centric sales and ongoing, detailed service.
We are also working aggressively to promote alliances with leading firms both domestically and abroad, and to reinforce our R&D pipeline in our franchise customer fields.
In proprietary drug discovery we focus on respiratory disease, otolaryngology, urology, and other key areas, utilizing our global network across Japan, the United States, and Europe and close collaboration between our divisions to verify drug synthesis, pharmacology, ADME (Absorption, Distribution, Metabolism, Excretion), and safety. These links underpin our efforts to discover original, new, world-class drugs.
Our production infrastructure features world-class manufacturing facilities and GMP*-based management, which will enable us to establish a system for providing a stable supply of high-quality products at low cost, and to build further trust.
As the environment surrounding the pharmaceutical industry grows increasingly turbulent both in Japan and abroad, KYORIN Pharmaceutical continues its efforts to establish a solid position in the industry, as we work to become a drug manufacturer that is trusted by both patients and medical professionals, and that is recognized by society for its contribution to good health.
* Good Manufacturing Practice: Standards for pharmaceutical manufacturing and quality assurance management
- Areas of Business :
- Drug discovery research, Research and development, Manufacturing, Sales
